Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Blood

Volumn 126, Issue 12, 2015, Pages 1452-1461

  Rook, Alain H ^a   Gelfand, Joel M ^a   Wysocka, Maria ^a   Troxel, Andrea B ^a   Benoit, Bernice ^a   Surber, Christian ^b,c   Elenitsas, Rosalie ^a   Buchanan, Marie A ^a   Leahy, Deborah S ^a   Watanabe, Rei ^d,e   Kirsch, Ilan R ^f   Kim, Ellen J ^a   Clark, Rachael A ^e,g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF TOKYO   (Japan)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f ADAPTIVE BIOTECHNOLOGIES   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 17; INTERLEUKIN 22; PERFORIN; RESIQUIMOD; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EFFECTOR CELL; FEMALE; FEVER; FLOW CYTOMETRY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MALE; MIDDLE AGED; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; SKIN DISEASE; SKIN EROSION; SKIN IRRITATION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOMA, T-CELL, CUTANEOUS; PATHOLOGY; SKIN; SKIN NEOPLASMS; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMIDAZOLES; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84942938920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-630335     Document Type: Article

References (24)

1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350(19):1978-1988.
2. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4): 798-812.
3. Willemze R, Jaffe ES, Burg G, et al. WHOEORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
4. Olsen E, Vonderheid E, Pimpinelli N, et al; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
5. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7): 857-866.
6. Hosing C, Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol. 2011;22(7):1471-1477.
7. Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol. 1995;154(3):1491-1498.
8. Rook AH, Kubin M, Fox FE, et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann N Y Acad Sci. 1996;795: 310-318.
9. Schön MP, Schön M. The small-molecule immune response modifier imiquimod-its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets. 2006;10(1):69-76.
10. Papadavid E, Stratigos AJ, Falagas ME. Imiquimod: An immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert Opin Pharmacother. 2007;8(11): 1743-1755.
11. Do JH, McLaughlin SS, Gaspari AA. Topical imiquimod therapy for cutaneous T-cell lymphoma. Skinmed. 2003;2(5):316-318.
12. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002; 218(1-2):74-86.
13. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174(3):1259-1268.
14. Urosevic M, Dummer R, Conrad C, et al. Diseaseindependent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005; 97(15):1143-1153.
15. Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat Rev Immunol. 2014; 14(6):417-428.
16. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009; 37(Database issue):D1006-D1012.
17. Lefranc MP. IMGT, the International ImMunoGeneTics Information System. Cold Spring Harb Protoc. 2011;2011(6):595-603.
18. Lefranc MP. IMGT, the International ImMunoGeneTics Information System. Methods Mol Biol. 2004;248:27-49.
19. Clark RA, Chong BF, Mirchandani N, et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol. 2006;126(5):1059-1070.
20. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA1 T cells are resident in normal skin. J Immunol. 2006;176(7):4431-4439.
21. Robins HS, Campregher PV, Srivastava SK, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114(19):4099-4107.
22. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3(3): 193-215.
23. Wysocka M, Newton S, Benoit BM, et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma. 2007; 7(8):524-534.
24. Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: A phase 1/2 study. Blood. 2012; 119(2):355-363.